Clinical Trials Logo

Clinical Trial Summary

Folic acid supplementation (1mg/d) is the standard recommendation for Canadian children with Sickle cell disease (SCD), even though it can provide up to six times the recommended intake amount for healthy children. There is growing concern that too much folic acid can be detrimental to health as high folate levels and circulating unmetabolized folic acid (UMFA), which occurs in blood with doses of folic acid as low as 0.2mg/d, have been associated with accelerated growth of some pre-cancerous cells, and altered DNA methylation and gene expression. To inform the efficacy and potential harm of high-dose folic acid supplementation in Canadian children with SCD, a double-blind randomized controlled cross-over trial is proposed. Children with SCD (n=36, aged 2-19 y) will be recruited from BC Children's Hospital and randomized to initially receive 1 mg/d folic acid or a placebo for 12-weeks (wk). After a 12-wk washout period, treatments will be reversed.


Clinical Trial Description

Blood samples will be collected at baseline and 12-wk of each treatment period (weeks 12, 24, and 36). Serum and RBC concentrations of total folate, different folate forms and clinical outcomes will be measured at baseline and after each treatment period. Dietary folate intake will be assessed at baseline. The objective of this study is to determine efficacy and potential harm of folic acid supplementation, versus no supplementation, in Canadian children with sickle cell disease. It is hypothesized that: (1) there will be no difference in mean RBC folate concentrations across folic acid and placebo groups after 12-wk, (2) none of the participants will have folate deficiency, and (3) compared to periods of no supplementation, during periods of high-dose folic acid supplementation participants will show no difference in clinical outcomes, but have higher plasma unmetabolized folic acid concentrations. Significance: There is a need to determine if the current clinical practice of high-dose folic acid supplementation is efficacious, and warranted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04011345
Study type Interventional
Source University of British Columbia
Contact
Status Completed
Phase N/A
Start date November 23, 2020
Completion date October 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06078696 - Siplizumab for Sickle Cell Disease Transplant Phase 1/Phase 2
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02561312 - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed NCT00890396 - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Recruiting NCT02286154 - Therapeutic Response Evaluation and Adherence Trial (TREAT) N/A
Completed NCT02857023 - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease N/A
Withdrawn NCT01925001 - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis Phase 2
Terminated NCT00122980 - Stroke With Transfusions Changing to Hydroxyurea Phase 3
Completed NCT00246077 - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport N/A
Completed NCT00094887 - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Phase 2
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Terminated NCT04091737 - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Phase 1
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04351698 - SMILES: Study of Montelukast in Sickle Cell Disease Phase 2/Phase 3
Not yet recruiting NCT06290401 - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD Phase 2